Ribociclib Inhibits P-gp-Mediated Multidrug Resistance in Human Epidermoid Carcinoma Cells

Lei Zhang, Biwei Ye, Yunfeng Lin, Yidong Li, Jing‐Quan Wang, Zhuo Chen, Fengfeng Ping, Zhe‐Sheng Chen, Zhe-Sheng ChenFrontiers in Pharmacology 2022 · DOI

TL;DR

This study reveals that the FDA-approved CDK4/6 inhibitor ribociclib (LEE011) can effectively reverse multidrug resistance (MDR) in cancer cells by inhibiting the P-glycoprotein (P-gp) transporter. Ribociclib works through a dual mechanism: it downregulates the expression of the P-gp pump at both the genetic and protein levels and directly interferes with its drug-efflux function, making resistant tumors sensitive to chemotherapy once again.

What Problem Does This Paper Address?

One of the biggest hurdles in cancer treatment is multidrug resistance (MDR). Even when a drug initially works, cancer cells often evolve "pumps" on their surface—most notably P-glycoprotein (P-gp)—that recognize and eject a wide variety of chemotherapeutic agents before they can reach their targets inside the cell.

While ribociclib is already a standard treatment for certain breast cancers, its potential to combat MDR in other solid tumors remained unclear. The authors investigated whether ribociclib could be repurposed or used in combination therapy to "clog" or "dismantle" these cellular bouncers, thereby restoring the efficacy of traditional drugs like doxorubicin and colchicine.

Methods

The researchers used a pair of human epidermoid carcinoma cell lines: KB-3-1 (the sensitive "parental" line) and KB-C2 (a resistant line that overexpresses P-gp).

Key techniques included:

  • MTT Assays: To measure cell viability and determine how ribociclib changes the potency ($IC_{50}$) of other chemotherapy drugs.
  • Western Blotting & RT-qPCR: To quantify changes in P-gp protein and mRNA levels, respectively.
  • ATPase Activity Assay: To determine if ribociclib directly interacts with the P-gp pump's "engine" (which consumes ATP to move drugs).
  • Accumulation & Efflux Assays: Using fluorescent doxorubicin to visualize and quantify how much drug stays inside the cells in the presence of ribociclib.
  • Molecular Docking: Computational modeling to predict exactly where and how ribociclib binds to the 3D structure of the P-gp protein.

Datasets

This was an experimental laboratory study and did not utilize large-scale public genomic or clinical datasets. The primary "data" generated were from the KB-3-1 and KB-C2 cell lines. Protein structures for docking were obtained via homology modeling using the Swiss Model platform based on known P-gp sequences.

Key Insights and Ideas

  • Direct Interaction: Ribociclib isn't just a passive bystander; it interacts directly with the drug-substrate binding site of P-gp. Docking studies showed it binds near the interface of the transmembrane domains and the nucleotide-binding domains.
  • The ATPase "Turbo" Effect: Ribociclib stimulated the basal activity of P-gp ATPase by 3.5-fold. In the world of ABC transporters, this usually indicates that the molecule is a substrate or a potent competitive inhibitor that keeps the pump busy while other drugs slip past.
  • Genetic Downregulation: Most interestingly, ribociclib significantly reduced the amount of P-gp produced. After 72 hours of treatment, ABCB1 (the gene for P-gp) mRNA levels dropped to just 5.6% of their normal levels.
  • Restored Sensitivity: By inhibiting the pump, ribociclib shifted the $IC_{50}$ of colchicine in resistant cells from the micromolar range back down toward the nanomolar range, effectively "re-sensitizing" the cancer.

Key Results

  • Potency: Ribociclib increased the efficacy of colchicine in resistant KB-C2 cells at concentrations of 3–9 µM.
  • ATPase Stimulation: The concentration required to increase basal P-gp ATPase activity by 50% ($EC_{50}$) was remarkably low at 0.04 µM.
  • Drug Accumulation: Co-treatment with ribociclib led to a ~2-fold increase in the intracellular accumulation of doxorubicin in resistant cells.
  • Expression Drop: Western blots confirmed a significant decrease in P-gp protein expression in KB-C2 cells following incubation with 9 µM ribociclib.

Limitations and Future Work

  • In Vitro Focus: The study was conducted entirely in cell cultures. While the results are promising, the complex environment of a living organism (pharmacokinetics, blood-brain barrier, etc.) could alter these interactions.
  • Concentration Levels: The 9 µM concentration used for some experiments is relatively high. Future studies need to determine if these effects occur at the plasma concentrations typically achieved in human patients.
  • Mechanism of Downregulation: While the paper proves that P-gp expression drops, the exact signaling pathway—how inhibiting CDK4/6 leads to the silencing of the ABCB1 gene—requires further mapping.
  • Animal Models: The authors acknowledge that the next logical step is animal studies to verify the biocompatibility and tumor-killing efficacy of these drug combinations in vivo.

Summary updated

Abstract

The efficacy of cancer chemotherapy can be attenuated or abrogated by multidrug resistance (MDR) in cancer cells. In this study, we determined the effect of the CDK4/6 inhibitor, ribociclib (or LEE011), on P-glycoprotein (P-gp)-mediated MDR in the human epidermoid carcinoma MDR cell line, KB-C2, which is widely used for studying P-gp-mediated MDR in cancers. The incubation of KB-C2 cells with ribociclib (3-9 µM) increased the efficacy of colchicine, a substrate for P-gp. The cell expression of P-gp was down-regulated at both translation and transcription levels. Furthermore, ribociclib produced a 3.5-fold increase in the basal activity of P-gp ATPase, and the concentration required to increase basal activity by 50% (EC<sub>50</sub>) was 0.04 μM. Docking studies indicated that ribociclib interacted with the drug-substrate binding site of P-gp. The short-term and long-term intracellular accumulation of doxorubicin greatly increased in the KB-C2 cells co-cultured with ribociclib, indicating ribociclib inhibited the drug efflux activity of P-gp. The results of our study indicate that LEE011 may be a potential agent for combined therapy of the cancers with P-gp mediated MDR.
BibTeX
@inproceedings{zhang2022ribociclib,
  author = {Lei Zhang and Biwei Ye and Yunfeng Lin and Yidong Li and Jing‐Quan Wang and Zhuo Chen and Fengfeng Ping and Zhe‐Sheng Chen and Zhe-Sheng Chen and Zhe-Sheng Chen},
  title = {{Ribociclib Inhibits P-gp-Mediated Multidrug Resistance in Human Epidermoid Carcinoma Cells}},
  booktitle = {Frontiers in Pharmacology},
  year = {2022},
  doi = {10.3389/fphar.2022.867128},
}
Figure